Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective real-world study of camrelizumab-related endocrine immune adverse events in advanced malignancies
ChiCTR2000035463Phase 4Not yet recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Sep 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab in cancer, sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: Impact and severity grading of immune-related endocrine events. Planned start Sep 2020; status: not yet recruiting.
02
Drugs
camrelizumab
03
Conditions
cancer
Beyond the preview
Go deeper on ChiCTR2000035463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000035463.